Drug intelligence / Profile preview

Shuanghuangzhi

Development stage: Unknown
Lead developer: Jilin Yizheng Pharmaceutical Group
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Shuanghuangzhi is a Traditional Chinese Medicine (TCM) formulation developed by Jilin Yizheng Pharmaceutical Group for the treatment of chronic cholecystitis. It is specifically indicated for patients presenting with liver and gallbladder damp-heat syndrome. The medication is formulated as a capsule and is intended to clear heat, promote diuresis, and soothe the liver and gallbladder. Clinical development has reached Phase II, with trials focusing on evaluating efficacy, safety, and dose-response relationships to support progression to Phase III.

Brand names: Shuanghuangzhi
Other names: Shuanghuangzhi capsule双黄止胶囊

Beyond the preview

Go deeper on Shuanghuangzhi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shuanghuangzhi.

Explore the full profile